Herantis Pharma Plc announced Results of proof-of-concept study demonstrating successful nanoforming of HER-096 into nanoparticles and further exploration the applicability of Nanoform's technology in the development of an oral dosage form based on HER-096 nanoparticles. Herantis has previously shown that HER-096 penetrates the blood brain barrier and enters the brain in therapeutic concentrations in healthy rats following subcutaneous administration. Subcutaneous administration will be used in Herantis' HER-096 first-in-human clinical study that is expected to commence in 2023.